{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 22,
  "pageCount": 24,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "DART stands for developmental and reproductive toxicology.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/22",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.5,
        "x": 0.25,
        "y": 0.85
      },
      "kind": "callout",
      "text": "No evidence of structural or off-target liabilities; on-target effects believed to be reversible",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47d23cfd-b39b-4fb9-a432-03f7ec8264e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.03,
        "y": 0.27
      },
      "kind": "list",
      "text": "Safety Pharmacology & Genotoxicity Studies: No findings anticipated to be of clinical relevance from a standard battery of nonclinical CNS, CV and respiratory safety pharmacology studies; Negative for genotoxicity; Negative for photoirradiation potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d3575e8-63c6-4ab5-8c6b-d5c577fac09e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.35,
        "y": 0.27
      },
      "kind": "list",
      "text": "Repeat Dose Toxicology Studies: Anticipated on-target effects related to KIT inhibition observed on spermatogenesis, hematology and pigmentation; Complete reversibility for these effects either observed or we believe can be achieved with a sufficient recovery period",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "267bb5a2-c934-4923-a08b-0bc1616ea241",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.3,
        "x": 0.67,
        "y": 0.27
      },
      "kind": "list",
      "text": "Ongoing Toxicology Program: Rat and dog chronic toxicology studies ongoing to support Phase 2 open label extension studies; DART program initiated, teratogenicity labeling expected with KIT inhibition, as with other immunology drug classes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45ded190-561f-4f52-aae7-6714d9a51484",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.25,
        "x": 0.67,
        "y": 0.64
      },
      "kind": "source-note",
      "text": "DART: developmental and reproductive toxicology",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71583f62-d815-4a77-9d22-59a78e2f9c8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "THB001: Nonclinical Safety and Toxicology Profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c33be8d-4df7-483e-a25d-b074ef6aaf05",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 18,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "f318ece6-0617-4060-a8a8-460a299bc4cc",
      "evidence": "The deck presents multiple upcoming clinical catalysts and a clear development plan.",
      "position": 1,
      "objective": "Can THB001 achieve quick wins and make a big impact in the treatment of mast cell-mediated diseases?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}